genOway Germany GmbH

The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1) to reduce high failure rates due to faulty candidate selection and false positives and (2) to identify all the potential candidates among the false negatives. There are thus great potential savings to be realized by making development more efficient. To help make these savings, genOway designs, develops and markets technologies and proprietary innovative genetically modified biological models. These solutions aim to increase the predictability and throughput of research in target validation, drug screening and pharmacological - toxicological studies.